CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones
inhibitor, in patients with relapsed or refractory acute myeloid leukemia (AML) as part of Phase 1. In Phase 2, assessment of ziftomenib wil...
Phase 1, Phase 2
Nashville, Tennessee, United States and 51 other locations
in treating pediatric and young adult patients with acute myeloid leukemia (AML) or acute leukemia of ambiguous lineage (ALAL) that...
Phase 1
Nashville, Tennessee, United States and 9 other locations
(bid) in approximately 540 participants with chronic lymphocytic leukemia (CLL). Participants will be enrolled into 3 following cohorts: tre...
Phase 3
Nashville, Tennessee, United States and 105 other locations
GDX012 is a novel cell therapy developed for the treatment of certain types of cancer, including Acute Myeloid Leukemia (AML). The main aims...
Phase 1, Phase 2
Nashville, Tennessee, United States and 13 other locations
chemotherapy regimen for the treatment of B-cell acute lymphoblastic leukemia. Part 1 of the study will optimize the dose of study drug (rux...
Phase 2
Nashville, Tennessee, United States and 110 other locations
This first-in-human study will evaluate RVU120 (SEL120), a novel small molecule CDK8/19 inhibitor, in patients with Acute Myeloid Leukemia (...
Phase 1
Nashville, Tennessee, United States and 9 other locations
Eligible untreated patients with FLT3 acute myeloid leukemia (AML) between the ages of 18 and 70 will be randomized to receive gilteritinib ...
Phase 2
Nashville, Tennessee, United States and 43 other locations
This is a Phase 1/2, multicenter, open-label study to evaluate the safety and efficacy of BEAM-201 in patients with relapsed/refractory T-ALL or T-LL...
Phase 1, Phase 2
Nashville, Tennessee, United States and 7 other locations
This study will evaluate the efficacy of uproleselan (GMI-1271), a specific E-selectin antagonist, in combination with chemotherapy to treat relapsed...
Phase 3
Nashville, Tennessee, United States and 69 other locations
The purpose of this study is to determine whether the combination of pevonedistat and azacitidine improves event-free survival (EFS) when compared wi...
Phase 3
Nashville, Tennessee, United States and 240 other locations
Clinical trials
Research sites
Resources
Legal